{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:30:26Z","timestamp":1793039426258,"version":"4.5.0"},"reference-count":430,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["IDIFEDER\/2017\/064"],"award-info":[{"award-number":["IDIFEDER\/2017\/064"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["PROMETEO\/2021\/024"],"award-info":[{"award-number":["PROMETEO\/2021\/024"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FEDER-PID2019-106230RB-I00"],"award-info":[{"award-number":["FEDER-PID2019-106230RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.biopha.2022.112911","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T06:00:34Z","timestamp":1649052034000},"page":"112911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Combined drug triads for synergic neuroprotection in retinal degeneration"],"prefix":"10.1016","volume":"149","author":[{"given":"Victoria","family":"Maneu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Lax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Miguel G.","family":"De Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio G.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112911_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1511\/2003.11.28","article-title":"How the retina works","volume":"91","author":"Kolb","year":"2003","journal-title":"Am. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072262","article-title":"Neuroprotective strategies for retinal ganglion cell degeneration: current status and challenges ahead","volume":"21","author":"Boia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.preteyeres.2014.07.001","article-title":"Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases","volume":"43","author":"Cuenca","year":"2014","journal-title":"Prog. Retin Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JAD-2010-080785","article-title":"Visual impairment in Alzheimer\u2019s disease: a critical review","volume":"21","author":"Kirby","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib5","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00702-009-0292-z","article-title":"Retinopathy in Parkinson disease","volume":"116","author":"Bodis-Wollner","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.biopha.2022.112911_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40478-018-0596-z","article-title":"Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson\u2019s disease","volume":"6","author":"Ortuno-Lizaran","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.biopha.2022.112911_bib7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.25897","article-title":"Dopaminergic retinal cell loss and visual dysfunction in Parkinson disease","volume":"88","author":"Ortuno-Lizaran","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00039.2005","article-title":"Calcium signaling and exocytosis in adrenal chromaffin cells","volume":"86","author":"Garcia","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2022.112911_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0896-6273(00)80983-6","article-title":"Vesicle pools and Ca2+ microdomains: new tools for understanding their roles in neurotransmitter release","volume":"20","author":"Neher","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2022.112911_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0006-3495(85)83804-2","article-title":"Compartmentalization of the submembrane calcium activity during calcium influx and its significance in transmitter release","volume":"48","author":"Simon","year":"1985","journal-title":"Biophys. J."},{"key":"10.1016\/j.biopha.2022.112911_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1083\/jcb.144.2.241","article-title":"Ca2+-induced Ca2+ release in chromaffin cells seen from inside the ER with targeted aequorin","volume":"144","author":"Alonso","year":"1999","journal-title":"J. Cell Biol."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2022.112911_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1469-7793.2000.00057.x","article-title":"Mitochondria and calcium: from cell signalling to cell death","volume":"529","author":"Duchen","year":"2000","journal-title":"J. Physiol."},{"key":"10.1016\/j.biopha.2022.112911_bib13","doi-asserted-by":"crossref","first-page":"C755","DOI":"10.1152\/ajpcell.1990.258.5.C755","article-title":"Mechanisms by which mitochondria transport calcium","volume":"258","author":"Gunter","year":"1990","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.biopha.2022.112911_bib14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1152\/physrev.1999.79.4.1127","article-title":"Mitochondrial transport of cations: channels, exchangers, and permeability transition","volume":"79","author":"Bernardi","year":"1999","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2022.112911_bib15","doi-asserted-by":"crossref","first-page":"C313","DOI":"10.1152\/ajpcell.1994.267.2.C313","article-title":"Mitochondrial calcium transport: physiological and pathological relevance","volume":"267","author":"Gunter","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.biopha.2022.112911_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1096\/fj.01-0630com","article-title":"Redistribution of Ca2+ among cytosol and organella during stimulation of bovine chromaffin cells","volume":"16","author":"Villalobos","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2022.112911_bib17","doi-asserted-by":"crossref","unstructured":"R.J.R. A, Calretinin and calbindin-D28k in rat brain: patterns of partial co-localization Title, (n.d.). \u3008https:\/\/doi.org\/10.1016\/0306\u20134522(92)90525\u20137\u3009.","DOI":"10.1016\/0306-4522(92)90525-7"},{"key":"10.1016\/j.biopha.2022.112911_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0197-0186(91)90070-T","article-title":"Radioimmunoassay of calretinin in the rat brain","volume":"19","author":"Winsky","year":"1991","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.biopha.2022.112911_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2990.1993.tb00443.x","article-title":"Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease","volume":"19","author":"Ince","year":"1993","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.biopha.2022.112911_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/cne.902800203","article-title":"Calcium-binding protein (calbindin-D28k) and parvalbumin immunocytochemistry: localization in the rat hippocampus with specific reference to the selective vulnerability of hippocampal neurons to seizure activity","volume":"280","author":"Sloviter","year":"1989","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib21","first-page":"496","article-title":"The effect of calcium on acetylcholine release from motor nerve terminals","volume":"161","author":"Katz","year":"1965","journal-title":"Proc. R. Soc. L B Biol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/35036035","article-title":"The versatility and universality of calcium signalling","volume":"1","author":"Berridge","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112911_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/neu.480250309","article-title":"Calcium regulation of gene expression in neuronal cells","volume":"25","author":"Ghosh","year":"1994","journal-title":"J. Neurobiol."},{"key":"10.1016\/j.biopha.2022.112911_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/27094","article-title":"Calcium--a life and death signal","volume":"395","author":"Berridge","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112911_bib25","series-title":"Therapeutic Targets","first-page":"123","article-title":"Multitarget drugs for stabilization of calcium cycling and neuroprotection in neurodegenerative diseases and stroke","author":"de Diego","year":"2012"},{"key":"10.1016\/j.biopha.2022.112911_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1474-9726.2007.00299.x","article-title":"Role of calcium in normal aging and neurodegeneration","volume":"6","author":"Toescu","year":"2007","journal-title":"Aging Cell"},{"key":"10.1016\/j.biopha.2022.112911_bib27","first-page":"563","article-title":"Myocardial fiber necrosis due to intracellular Ca overload-a new principle in cardiac pathophysiology","volume":"4","author":"Fleckenstein","year":"1974","journal-title":"Recent Adv. Stud. Card. Struct. Metab."},{"key":"10.1016\/j.biopha.2022.112911_bib28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1083\/jcb.82.3.811","article-title":"Agonist-induced myopathy at the neuromuscular junction is mediated by calcium","volume":"82","author":"Leonard","year":"1979","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112911_bib29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.386513","article-title":"Calcium dependence of toxic cell death: a final common pathway","volume":"206","author":"Schanne","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112911_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1096\/fasebj.9.2.7781924","article-title":"Calcium-mediated cell injury and cell death","volume":"9","author":"Trump","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2022.112911_bib31","doi-asserted-by":"crossref","first-page":"39695","DOI":"10.1074\/jbc.M102334200","article-title":"Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death","volume":"276","author":"Cano-Abad","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112911_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0166-2236(92)90103-F","article-title":"Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium","volume":"15","author":"Franklin","year":"1992","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib33","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1523\/JNEUROSCI.07-07-02203.1987","article-title":"The role of depolarization in the survival and differentiation of cerebellar granule cells in culture","volume":"7","author":"Gallo","year":"1987","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib34","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1073\/pnas.86.16.6421","article-title":"Role of Ca2+ channels in the ability of membrane depolarization to prevent neuronal death induced by trophic-factor deprivation: evidence that levels of internal Ca2+ determine nerve growth factor dependence of sympathetic ganglion cells","volume":"86","author":"Koike","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.112911_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/bj3570137","article-title":"Elevated extracellular [K+] inhibits death-receptor- and chemical-mediated apoptosis prior to caspase activation and cytochrome c release","volume":"357","author":"Thompson","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2022.112911_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2006.08.084","article-title":"Depolarization preconditioning produces cytoprotection against veratridine-induced chromaffin cell death","volume":"553","author":"Orozco","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0955-0674(00)00228-3","article-title":"Ion homeostasis and apoptosis","volume":"13","author":"Yu","year":"2001","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112911_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1523\/JNEUROSCI.22-01-00114.2002","article-title":"Multiple channel interactions explain the protection of sympathetic neurons from apoptosis induced by nerve growth factor deprivation","volume":"22","author":"Xia","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib39","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-8993(89)90465-4","article-title":"The role of dihydropyridine-sensitive voltage-gated calcium channels in potassium-mediated neuronal survival","volume":"502","author":"Collins","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2022.112911_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1749-6632.1994.tb44410.x","article-title":"Elevated intracellular calcium blocks programmed neuronal death","volume":"747","author":"Franklin","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nrm1150","article-title":"Regulation of cell death: the calcium-apoptosis link","volume":"4","author":"Orrenius","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112911_bib42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1523\/JNEUROSCI.07-02-00369.1987","article-title":"Ionic dependence of glutamate neurotoxicity","volume":"7","author":"Choi","year":"1987","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/0896-6273(88)90162-6","article-title":"Glutamate neurotoxicity and diseases of the nervous system","volume":"1","author":"Choi","year":"1988","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2022.112911_bib44","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.7901908","article-title":"Oxidative stress, glutamate, and neurodegenerative disorders","volume":"262","author":"Coyle","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112911_bib45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJM199403033300907","article-title":"Excitatory amino acids as a final common pathway for neurologic disorders","volume":"330","author":"Lipton","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib46","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1471-4159.1984.tb05396.x","article-title":"Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis","volume":"43","author":"Benveniste","year":"1984","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112911_bib47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0165-6147(90)90184-A","article-title":"Excitatory amino acid neurotoxicity and neurodegenerative disease","volume":"11","author":"Meldrum","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1523\/JNEUROSCI.12-01-00056.1992","article-title":"Glutamate uptake disguises neurotoxic potency of glutamate agonists in cerebral cortex in dissociated cell culture","volume":"12","author":"Rosenberg","year":"1992","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0031-6997(25)00025-0","article-title":"Excitatory amino acid receptors in the vertebrate central nervous system","volume":"41","author":"Collingridge","year":"1989","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2022.112911_bib50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1749-6632.1999.tb11320.x","article-title":"Expression mechanisms underlying NMDA receptor-dependent long-term potentiation","volume":"868","author":"Nicoll","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib51","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1523\/JNEUROSCI.17-16-06179.1997","article-title":"Global ischemia induces downregulation of Glur2 mRNA and increases AMPA receptor-mediated Ca2+ influx in hippocampal CA1 neurons of gerbil","volume":"17","author":"Gorter","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-8993(88)90765-2","article-title":"Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced","volume":"451","author":"Novelli","year":"1988","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2022.112911_bib53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000089620","article-title":"Excitotoxicity and amyotrophic lateral sclerosis","volume":"2","author":"Van Damme","year":"2005","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib54","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1046\/j.1471-4159.1994.63020584.x","article-title":"Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated CA2+ and Na+: implications for neurodegeneration","volume":"63","author":"Dykens","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112911_bib55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/1097-4547(20010301)63:5<377::AID-JNR1032>3.0.CO;2-#","article-title":"N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx","volume":"63","author":"Urushitani","year":"2001","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.biopha.2022.112911_bib56","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0166-2236(88)90200-7","article-title":"Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage","volume":"11","author":"Choi","year":"1988","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib57","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1152\/jn.2002.88.3.1279","article-title":"GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity","volume":"88","author":"Van Damme","year":"2002","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.biopha.2022.112911_bib58","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1600-0420.2005.00565.x","article-title":"Neuronal versus glial cell swelling in the ischaemic retina","volume":"83","author":"Bringmann","year":"2005","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.biopha.2022.112911_bib59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0361-9230(03)00070-4","article-title":"Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma","volume":"62","author":"Osborne","year":"2004","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.biopha.2022.112911_bib60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.survophthal.2007.12.006","article-title":"The role of calcium-activated protease calpain in experimental retinal pathology","volume":"53","author":"Azuma","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib61","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1167\/iovs.05-0248","article-title":"Activation of multiple pathways during photoreceptor apoptosis in the rd mouse","volume":"46","author":"Doonan","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib62","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1167\/iovs.07-0287","article-title":"A key role for calpains in retinal ganglion cell death","volume":"48","author":"McKernan","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib63","doi-asserted-by":"crossref","first-page":"12242","DOI":"10.1073\/pnas.0505138102","article-title":"Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma","volume":"102","author":"Huang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.112911_bib64","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1167\/iovs.09-4364","article-title":"Calpain activation in experimental glaucoma","volume":"51","author":"Huang","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib65","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1126\/science.247.4949.1474","article-title":"The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity","volume":"247","author":"Weiss","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112911_bib66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/jop.1990.6.293","article-title":"Effect of the calcium antagonist, nifedipine, on ischemic retinal dysfunction","volume":"6","author":"Crosson","year":"1990","journal-title":"J. Ocul. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib67","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/292040","article-title":"Effects of calcium ion, calpains, and calcium channel blockers on retinitis pigmentosa","volume":"2011","author":"Nakazawa","year":"2011","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib68","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1177\/112067210301303S08","article-title":"Pharmacological strategies to block rod photoreceptor apoptosis caused by calcium overload: a mechanistic target-site approach to neuroprotection","volume":"13 Suppl 3","author":"Fox","year":"2003","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib69","first-page":"1456","article-title":"Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity","volume":"43","author":"Osborne","year":"2002","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib70","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/archopht.1992.01080180134041","article-title":"Protective effects of flunarizine on ischemic injury in the rat retina","volume":"110","author":"Takahashi","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib71","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/eye.2011.7","article-title":"Calcium overload is associated with lipofuscin formation in human retinal pigment epithelial cells fed with photoreceptor outer segments","volume":"25","author":"Zhang","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2022.112911_bib72","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1167\/iovs.06-0890","article-title":"Alpha2 adrenergic receptor-mediated modulation of cytosolic Ca++ signals at the inner plexiform layer of the rat retina","volume":"48","author":"Dong","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib73","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(96)01393-5","article-title":"In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent","volume":"751","author":"Osborne","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2022.112911_bib74","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/BF02153655","article-title":"Histologic changes in the inner retina of albino rats following intravitreal injection of monosodium L-glutamate","volume":"223","author":"Sisk","year":"1985","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib75","first-page":"1618","article-title":"Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine","volume":"37","author":"Vorwerk","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/archopht.1996.01100130295012","article-title":"Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma","volume":"114","author":"Dreyer","year":"1996","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib77","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0006-8993(98)00212-1","article-title":"MK801-a neuroprotectant in rat hypertensive eyes","volume":"792","author":"Chaudhary","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2022.112911_bib78","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1167\/iovs.05-0754","article-title":"Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo","volume":"47","author":"Guo","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib79","first-page":"1063","article-title":"Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia","volume":"39","author":"Lagreze","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib80","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mce.2007.12.009","article-title":"Physiology and pathology of somatostatin in the mammalian retina: a current view","volume":"286","author":"Cervia","year":"2008","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.biopha.2022.112911_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134337","article-title":"Activation of somatostatin receptor 5 suppresses T-type Ca(2+) channels through NO\/cGMP\/PKG signaling pathway in rat retinal ganglion cells","volume":"708","author":"Li","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2022.112911_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S0952523801181095","article-title":"Somatostatin inhibits calcium influx into rat rod bipolar cell axonal terminals","volume":"18","author":"Johnson","year":"2001","journal-title":"Vis. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib83","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1523\/JNEUROSCI.20-02-00649.2000","article-title":"Novel mechanism of massive photoreceptor degeneration caused by mutations in the trp gene of Drosophila","volume":"20","author":"Yoon","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib84","series-title":"Photoreceptors Calcium. Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/978-1-4615-0121-3_34","article-title":"The TRP calcium channel and retinal degeneration","author":"Minke","year":"2002"},{"key":"10.1016\/j.biopha.2022.112911_bib85","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1479-7364-5-2-108","article-title":"Transient receptor potential (TRP) gene superfamily encoding cation channels","volume":"5","author":"Pan","year":"2011","journal-title":"Hum. Genom."},{"key":"10.1016\/j.biopha.2022.112911_bib86","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1523\/JNEUROSCI.0359-11.2011","article-title":"The polymodal ion channel transient receptor potential vanilloid 4 modulates calcium flux, spiking rate, and apoptosis of mouse retinal ganglion cells","volume":"31","author":"Ryskamp","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib87","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1167\/iovs.08-2321","article-title":"TRPV1: contribution to retinal ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic pressure","volume":"50","author":"Sappington","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib88","doi-asserted-by":"crossref","first-page":"30583","DOI":"10.1038\/srep30583","article-title":"TRPV4 regulates calcium homeostasis, cytoskeletal remodeling, conventional outflow and intraocular pressure in the mammalian eye","volume":"6","author":"Ryskamp","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112911_bib89","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/iub.91","article-title":"Calcium ions in neuronal degeneration","volume":"60","author":"Wojda","year":"2008","journal-title":"IUBMB Life"},{"key":"10.1016\/j.biopha.2022.112911_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022181","article-title":"Calpain and PARP activation during photoreceptor cell death in P23H and S334ter rhodopsin mutant rats","volume":"6","author":"Kaur","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112911_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.325","article-title":"Unfolded protein response-induced dysregulation of calcium homeostasis promotes retinal degeneration in rat models of autosomal dominant retinitis pigmentosa","volume":"7","author":"Shinde","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib92","doi-asserted-by":"crossref","first-page":"17366","DOI":"10.1073\/pnas.0606276103","article-title":"Apoptosis in retinal degeneration involves cross-talk between apoptosis-inducing factor (AIF) and caspase-12 and is blocked by calpain inhibitors","volume":"103","author":"Sanges","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.112911_bib93","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/cdd.2014.203","article-title":"Lysosomal membrane permeabilization and autophagy blockade contribute to photoreceptor cell death in a mouse model of retinitis pigmentosa","volume":"22","author":"Rodr\u00edguez-Muela","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2022.112911_bib94","doi-asserted-by":"crossref","first-page":"H171","DOI":"10.1152\/ajpheart.00699.2009","article-title":"Glucose enhances expression of TRPC1 and calcium entry in endothelial cells","volume":"298","author":"Bishara","year":"2010","journal-title":"Am. J. Physiol. Hear. Circ. Physiol."},{"key":"10.1016\/j.biopha.2022.112911_bib95","first-page":"2371","article-title":"Calcium entry mediates hyperglycemia-induced apoptosis through Ca(2+)\/calmodulin-dependent kinase II in retinal capillary endothelial cells","volume":"18","author":"Li","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.biopha.2022.112911_bib96","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0304-4165(70)90096-6","article-title":"Glutathione metabolism of the red cells effect of glutathione reductase deficiency on the stimulation of hexose monophosphate shunt under oxidative stress","volume":"215","author":"Paniker","year":"1970","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.biopha.2022.112911_bib97","first-page":"3","article-title":"On the formation of hydrogen peroxide and oxygen radicals in heart mitochondria","volume":"7","author":"Loschen","year":"1975","journal-title":"Recent Adv. Stud. Card. Struct. Metab."},{"key":"10.1016\/j.biopha.2022.112911_bib98","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0891-5849(00)00317-8","article-title":"Mitochondrial free radical generation, oxidative stress, and aging","volume":"29","author":"Cadenas","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib99","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112911_bib100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.preteyeres.2010.11.002","article-title":"Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies","volume":"30","author":"Yu-Wai-Man","year":"2011","journal-title":"Prog. Retin Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib101","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/ars.2007.9.233","article-title":"Sources and targets of reactive oxygen species in synaptic plasticity and memory","volume":"9","author":"Kishida","year":"2007","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.biopha.2022.112911_bib102","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free radicals and antioxidants in normal physiological functions and human disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112911_bib103","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1089\/ars.2005.7.1140","article-title":"Production of reactive oxygen species in brain mitochondria: contribution by electron transport chain and non-electron transport chain sources","volume":"7","author":"Adam-Vizi","year":"2005","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.biopha.2022.112911_bib104","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.neuroscience.2008.10.015","article-title":"alpha-Ketoglutarate dehydrogenase contributes to production of reactive oxygen species in glutamate-stimulated hippocampal neurons in situ","volume":"158","author":"Zundorf","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2022.112911_bib105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2741\/3303","article-title":"Crosstalk signaling between mitochondrial Ca2+ and ROS","volume":"14","author":"Feissner","year":"2009","journal-title":"Front. Biosci. (Landmark Ed. )"},{"key":"10.1016\/j.biopha.2022.112911_bib106","first-page":"1352","article-title":"SR\/ER-mitochondrial local communication: calcium and ROS","volume":"2009","author":"Csordas","year":"1787","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.112911_bib107","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1098\/rstb.2005.1759","article-title":"Cross talk between Ca2+ and redox signalling cascades in muscle and neurons through the combined activation of ryanodine receptors\/Ca2+ release channels","volume":"360","author":"Hidalgo","year":"2005","journal-title":"Philos. Trans. R. Soc. L B Biol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib108","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bbabio.2009.03.010","article-title":"Mitochondrial calcium function and dysfunction in the central nervous system","volume":"1787","author":"Nicholls","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.112911_bib109","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1471-4159.2011.07527.x","article-title":"The phosphorylation status of extracellular-regulated kinase 1\/2 in astrocytes and neurons from rat hippocampus determines the thrombin-induced calcium release and ROS generation","volume":"119","author":"Zundorf","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112911_bib110","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1167\/iovs.07-1363","article-title":"Expression of nitrotyrosine and oxidative consequences in the trabecular meshwork of patients with primary open-angle glaucoma","volume":"49","author":"Fernandez-Durango","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib111","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2012.09.008","article-title":"Oxidative stress and mitochondrial dysfunction in glaucoma","volume":"13","author":"Chrysostomou","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9060561","article-title":"Update on the effects of antioxidants on diabetic retinopathy: in vitro experiments, animal studies and clinical trials","volume":"9","author":"Garcia-Medina","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2022.112911_bib113","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1167\/iovs.07-0170","article-title":"Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage","volume":"48","author":"Liu","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib114","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/bs.pbr.2015.06.001","article-title":"Oxidative stress and mitochondrial failure in the pathogenesis of glaucoma neurodegeneration","volume":"220","author":"Pinazo-Duran","year":"2015","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.biopha.2022.112911_bib115","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/768026","article-title":"Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration","volume":"2014","author":"Blasiak","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2022.112911_bib116","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3934\/molsci.2016.2.196","article-title":"Oxidative stress, innate immunity, and age-related macular degeneration","volume":"3","author":"Shaw","year":"2016","journal-title":"AIMS Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib117","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/cells10010064","article-title":"The impact of oxidative stress on blood-retinal barrier physiology in age-related macular degeneration","volume":"10","author":"Tisi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.112911_bib118","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/antiox9040347","article-title":"The relevance of oxidative stress in the pathogenesis and therapy of retinal dystrophies","volume":"9","author":"Dom\u00e8nech","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2022.112911_bib119","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3390\/antiox10111743","article-title":"Dietary antioxidants in age-related macular degeneration and glaucoma","volume":"10","author":"Dziedziak","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2022.112911_bib120","doi-asserted-by":"crossref","unstructured":"J.J. Garcia-Medina, V. Zanon-Moreno, M.D. Pinazo-Duran, E. Foulquie-Moreno, E. Foulquie-Moreno, R.P. Casaroli-Marano, M. Del-Rio-Vellosillo, Oxidative stress in diabetic retinopathy, in: V.R. Preedy (Ed.), Diabetes, 2020, pp. 49\u201357. https:\/\/doi.org\/10.1016\/B978\u20130-12\u2013815776-3.00005-X.","DOI":"10.1016\/B978-0-12-815776-3.00005-X"},{"key":"10.1016\/j.biopha.2022.112911_bib121","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3420187","article-title":"The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy","volume":"2018","author":"Wu","year":"2018","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.biopha.2022.112911_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197170","article-title":"Oxidative stress and microglial response in retinitis pigmentosa","volume":"21","author":"Murakami","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib123","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s12276-020-0460-7","article-title":"Preclinical pharmacology of a lipophenol in a mouse model of light-induced retinopathy","volume":"52","author":"Taveau","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128395","article-title":"Dietary supplement enriched in antioxidants and omega-3 protects from progressive light-induced retinal degeneration","volume":"10","author":"Ramchani-Ben Othman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112911_bib125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.preteyeres.2017.08.004","article-title":"The mechanism of cone cell death in Retinitis Pigmentosa","volume":"62","author":"Campochiaro","year":"2018","journal-title":"Prog. Retin Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib126","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15569527.2019.1685535","article-title":"(Z)-7,4\u2019-Dimethoxy-6-hydroxy-aurone-4-O-\u03b2-glucopyranoside mitigates retinal degeneration in Rd10 mouse model through inhibiting oxidative stress and inflammatory responses","volume":"39","author":"Chen","year":"2020","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.biopha.2022.112911_bib127","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0031-6997(25)06930-3","article-title":"Purinergic nerves","volume":"24","author":"Burnstock","year":"1972","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2022.112911_bib128","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/279541a0","article-title":"ATP induces nucleotide permeability in rat mast cells","volume":"279","author":"Cockcroft","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112911_bib129","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/S0021-9258(18)61477-2","article-title":"Extracellular ATP4- promotes cation fluxes in the J774 mouse macrophage cell line","volume":"262","author":"Steinberg","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112911_bib130","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1021\/jm020046y","article-title":"Purine and pyrimidine (P2) receptors as drug targets","volume":"45","author":"Jacobson","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112911_bib131","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/med.21710","article-title":"The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases","volume":"40","author":"Calzaferri","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2022.112911_bib132","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.153.5.2168","article-title":"Tenidap modulates cytoplasmic pH and inhibits anion transport in vitro. II. Inhibition of IL-1 beta production from ATP-treated monocytes and macrophages","volume":"153","author":"Laliberte","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2022.112911_bib133","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1172\/JCI117770","article-title":"The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role","volume":"95","author":"Falzoni","year":"1995","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2022.112911_bib134","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0167-5699(95)80045-X","article-title":"The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death","volume":"16","author":"Virgilio","year":"1995","journal-title":"Immunol. Today"},{"key":"10.1016\/j.biopha.2022.112911_bib135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jnc.13607","article-title":"Neuroinflammation: the devil is in the details","volume":"139","author":"DiSabato","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2022.112911_bib136","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2022.112911_bib137","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1113\/jphysiol.2003.047977","article-title":"ATP: a vasoactive signal in the pericyte-containing microvasculature of the rat retina","volume":"551","author":"Kawamura","year":"2003","journal-title":"J. Physiol."},{"key":"10.1016\/j.biopha.2022.112911_bib138","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.preteyeres.2011.06.001","article-title":"Purinergic signaling involved in Muller cell function in the mammalian retina","volume":"30","author":"Wurm","year":"2011","journal-title":"Prog. Retin Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib139","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.exer.2014.08.009","article-title":"Purines in the eye: recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, Muller cells, lens, trabecular meshwork, cornea and lacrimal gland","volume":"127","author":"Sanderson","year":"2014","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cne.20045","article-title":"Synaptic localization of P2X7 receptors in the rat retina","volume":"472","author":"Puthussery","year":"2004","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029990","article-title":"Rod and cone pathway signalling is altered in the P2X7 receptor knock out mouse","volume":"7","author":"Vessey","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112911_bib142","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tins.2009.01.001","article-title":"Purinergic signaling in special senses","volume":"32","author":"Housley","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib143","doi-asserted-by":"crossref","unstructured":"M.M. Ward, T. Puthussery, K.A. Vessey, E.L. Fletcher, The Role of Purinergic Receptors in Retinal Function and Disease, 2010, pp. 385\u2013391. https:\/\/doi.org\/10.1007\/978-1-4419-1399-9_44.","DOI":"10.1007\/978-1-4419-1399-9_44"},{"key":"10.1016\/j.biopha.2022.112911_bib144","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1460-9568.2006.04895.x","article-title":"Evidence for the involvement of purinergic P2X receptors in outer retinal processing","volume":"24","author":"Puthussery","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib145","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11302-016-9522-7","article-title":"P2X7R modulation of visually evoked synaptic responses in the retina","volume":"12","author":"Chavda","year":"2016","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2022.112911_bib146","doi-asserted-by":"crossref","DOI":"10.1017\/S0952523817000128","article-title":"Purinergic modulation of frog electroretinographic responses: the role of the ionotropic receptor P2X7","volume":"34","author":"Kupenova","year":"2017","journal-title":"Vis. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib147","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11302-008-9125-z","article-title":"The P2X(7) receptor in retinal ganglion cells: a neuronal model of pressure-induced damage and protection by a shifting purinergic balance","volume":"4","author":"Mitchell","year":"2008","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2022.112911_bib148","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuropharm.2015.05.005","article-title":"Purinergic signaling in retinal degeneration and regeneration","volume":"104","author":"Reichenbach","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2022.112911_bib149","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.biocel.2010.06.021","article-title":"Microglia: proliferation and activation driven by the P2X7 receptor","volume":"42","author":"Monif","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.biopha.2022.112911_bib150","first-page":"2289","article-title":"P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model","volume":"17","author":"Dong","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2022.112911_bib151","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1111\/j.1460-9568.2007.05528.x","article-title":"Acute retinal ganglion cell injury caused by intraocular pressure spikes is mediated by endogenous extracellular ATP","volume":"25","author":"Resta","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib152","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/IJG.0b013e31818c6ef6","article-title":"Friend or foe? Resolving the impact of glial responses in glaucoma","volume":"18","author":"Johnson","year":"2009","journal-title":"J. Glaucoma."},{"key":"10.1016\/j.biopha.2022.112911_bib153","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cne.22516","article-title":"Early microglia activation in a mouse model of chronic glaucoma","volume":"519","author":"Bosco","year":"2011","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib154","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1742-2094-9-92","article-title":"IOP induces upregulation of GFAP and MHC-II and microglia reactivity in mice retina contralateral to experimental glaucoma","volume":"9","author":"Gallego","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2022.112911_bib155","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/glia.20516","article-title":"Reactive nonproliferative gliosis predominates in a chronic mouse model of glaucoma","volume":"55","author":"Inman","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2022.112911_bib156","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1167\/iovs.10-5407","article-title":"Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling","volume":"51","author":"Luo","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043602","article-title":"Early reduction of microglia activation by irradiation in a model of chronic glaucoma","volume":"7","author":"Bosco","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112911_bib158","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00441-013-1666-y","article-title":"The role of Muller glia and microglia in glaucoma","volume":"353","author":"Seitz","year":"2013","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.biopha.2022.112911_bib159","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.brainresbull.2003.07.005","article-title":"Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma","volume":"62","author":"Neufeld","year":"2004","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.biopha.2022.112911_bib160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040065","article-title":"Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma","volume":"7","author":"Roh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112911_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.108953","article-title":"Minocycline suppresses disease-associated microglia (DAM) in a model of photoreceptor cell degeneration","volume":"217","author":"Ozaki","year":"2022","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib162","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.033597","article-title":"Immunomodulation with minocycline rescues retinal degeneration in juvenile Neuronal Ceroid Lipofuscinosis (jNCL) mice highly susceptible to light damage","author":"Dannhausen","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.biopha.2022.112911_bib163","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12974-015-0431-4","article-title":"Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration","volume":"12","author":"Scholz","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2022.112911_bib164","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1167\/iovs.10-6172","article-title":"Activation of P2X receptors induces apoptosis in human retinal pigment epithelium","volume":"52","author":"Yang","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib165","article-title":"Targeting the P2X7 receptor in age-related macular degeneration","volume":"1","author":"Yang","year":"2017","journal-title":"Vis"},{"key":"10.1016\/j.biopha.2022.112911_bib166","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ajpath.2017.04.016","article-title":"Loss of function of P2X7 receptor scavenger activity in aging mice: a novel model for investigating the early pathogenesis of age-related macular degeneration","volume":"187","author":"Vessey","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.112911_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100825","article-title":"Age-related macular degeneration: a two-level model hypothesis","volume":"76","author":"Rozing","year":"2020","journal-title":"Prog. Retin Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib168","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708259","article-title":"Modulation of three key innate immune pathways for the most common retinal degenerative diseases","volume":"10","author":"Akhtar-Schafer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib169","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4239\/wjd.v5.i2.141","article-title":"Role of P2X7 receptors in the development of diabetic retinopathy","volume":"5","author":"Sugiyama","year":"2014","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.biopha.2022.112911_bib170","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00592-019-01343-4","article-title":"Pharmacological blockade of the P2X7 receptor reverses retinal damage in a rat model of type 1 diabetes","volume":"56","author":"Clapp","year":"2019","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.biopha.2022.112911_bib171","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.3389\/fimmu.2019.02958","article-title":"The CD40-ATP-P2X 7 receptor pathway: cell to cell cross-talk to promote inflammation and programmed cell death of endothelial cells","volume":"10","author":"Subauste","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2022.112911_bib172","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0014-4835(02)00332-9","article-title":"Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration","volume":"76","author":"Gupta","year":"2003","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib173","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1167\/iovs.03-0301","article-title":"Proliferation of microglia, but not photoreceptors, in the outer nuclear layer of the rd-1 mouse","volume":"45","author":"Zeiss","year":"2004","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib174","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.15252\/emmm.201505298","article-title":"Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration","volume":"7","author":"Zhao","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/cne.21964","article-title":"Extracellular ATP induces retinal photoreceptor apoptosis through activation of purinoceptors in rodents","volume":"513","author":"Puthussery","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib176","unstructured":"No Title, (n.d.). \u3008https:\/\/clinicaltrials.gov\/\u3009."},{"key":"10.1016\/j.biopha.2022.112911_bib177","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00061198-199400320-00001","article-title":"The ocular hypertension treatment study","volume":"3","author":"Kass","year":"1994","journal-title":"J. Glaucoma."},{"key":"10.1016\/j.biopha.2022.112911_bib178","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/archophthalmol.2010.304","article-title":"[Canadian glaucoma study:] 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change (Archives of Ophthalmology (2010), 128, 10, (1249-1255))","volume":"128","author":"Chauhan","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib179","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jclinepi.2008.04.012","article-title":"A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure","volume":"62","author":"van der Valk","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.biopha.2022.112911_bib180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045079","article-title":"Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112911_bib181","first-page":"111","article-title":"Novel pharmacologic candidates for treatment of primary open-angle glaucoma","volume":"90","author":"Lu","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib182","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41433-019-0671-0","article-title":"New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost","volume":"34","author":"Mehran","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.biopha.2022.112911_bib183","doi-asserted-by":"crossref","unstructured":"S. He, D.L. Stankowska, D.Z. Ellis, R.R. Krishnamoorthy, T. Yorio, Targets of Neuroprotection in Glaucoma, (n.d.). \u3008https:\/\/doi.org\/10.1089\/jop.2017.0041\u3009.","DOI":"10.1089\/jop.2017.0041"},{"key":"10.1016\/j.biopha.2022.112911_bib184","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1750-1326-6-4","article-title":"Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons","volume":"6","author":"Lambert","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.biopha.2022.112911_bib185","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","article-title":"A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study","volume":"151","author":"Krupin","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib186","first-page":"112","article-title":"Glaucoma y antioxidantes: revisi\u00f3n sistem\u00e1tica","volume":"91","author":"Giaquinta Aranda","year":"2017","journal-title":"Rev. Mex. Oftalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib187","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H","article-title":"Retinal and choroidal neovascularization","volume":"184","author":"Campochiaro","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2022.112911_bib188","doi-asserted-by":"crossref","unstructured":"P.A. Keane, G. De Salvo, D.A. Sim, S. Goverdhan, R. Agrawal, A. Tufai, Clinical Ophthalmology Dovepress Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration, 2015. \u3008https:\/\/doi.org\/10.2147\/OPTH.S59012\u3009.","DOI":"10.2147\/OPTH.S59012"},{"key":"10.1016\/j.biopha.2022.112911_bib189","first-page":"12","article-title":"The burden of neovascular age-related macular degeneration: a patient\u2019s perspective","author":"Spooner","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib190","first-page":"552","article-title":"Age-related macular degeneration: a review of current therapies and new treatments","volume":"83","author":"Kniggendorf","year":"2020","journal-title":"Arq. Bras. Oftalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib191","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study","volume":"197","author":"Liu","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib192","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2022.112911_bib193","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3928\/23258160-20170130-02","article-title":"An overview of the fovista and rinucumab trials and the fate of anti-PDGF medications","volume":"48","author":"Dunn","year":"2017","journal-title":"Ophthalmic Surg. Lasers Imaging Retin"},{"key":"10.1016\/j.biopha.2022.112911_bib194","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.oret.2017.03.003","article-title":"Phase I trial of anti\u2013vascular endothelial growth factor\/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration","volume":"1","author":"Chakravarthy","year":"2017","journal-title":"Ophthalmol. Retin."},{"key":"10.1016\/j.biopha.2022.112911_bib195","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2022.112911_bib196","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1476-5381.2010.01118.x","article-title":"Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration","volume":"162","author":"Sabbadini","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib197","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1261754","article-title":"Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity","volume":"346","author":"Fowler","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112911_bib198","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-018-2554-7","article-title":"Pharmaceutical development of AAV-based gene therapy products for the eye","volume":"36","author":"Rodrigues","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2022.112911_bib199","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ophtha.2014.09.036","article-title":"Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration","volume":"122","author":"Csaky","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2022.112911_bib200","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/jcm9010216","article-title":"Do genomic factors play a role in diabetic retinopathy?","volume":"9","author":"Cabrera","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib201","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.visres.2017.02.011","article-title":"Diabetic retinopathy, metabolic memory and epigenetic modifications","volume":"139","author":"Kowluru","year":"2017","journal-title":"Vis. Res."},{"key":"10.1016\/j.biopha.2022.112911_bib202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/3096470","article-title":"Adjuvant therapies in diabetic retinopathy as an early approach to delay its progression: the importance of oxidative stress and inflammation","volume":"2020","author":"Robles-Rivera","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2022.112911_bib203","doi-asserted-by":"crossref","first-page":"637","DOI":"10.5301\/EJO.2010.6212","article-title":"A 5-year follow-up of antioxidant supplementation in type 2 diabetic retinopathy","volume":"21","author":"Garcia-Medina","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib204","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/bjophthalmol-2014-306534","article-title":"The diabetes visual function supplement study ( DiVFuSS)","volume":"100","author":"Chous","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib205","first-page":"303","article-title":"Application of Lutein and Zeaxanthin in nonproliferative diabetic retinopathy","volume":"4","author":"Hu","year":"2011","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib206","doi-asserted-by":"crossref","unstructured":"M. Lafuente, L. Ort\u00edn, M. Argente, J.L. Guindo, M.D. L\u00f3pez-Bernal, F.J. L\u00f3pez-Rom\u00e1n, J.C. Domingo, J. Lajara, Three-year outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema, 2019. \u3008https:\/\/eudract.ema.europa.eu\/\u3009.","DOI":"10.1097\/IAE.0000000000002114"},{"key":"10.1016\/j.biopha.2022.112911_bib207","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/bjophthalmol-2018-312244","article-title":"Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial","volume":"103","author":"Ahmadieh","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib208","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2018.03.007","article-title":"Effects of crocin on diabetic maculopathy: a placebo-controlled randomized clinical trial","volume":"190","author":"Sepahi","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib209","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.592274","article-title":"Anti-inflammatory effect of curcumin, homotaurine, and vitamin D3 on human vitreous in patients with diabetic retinopathy","volume":"11","author":"Filippelli","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2017.10.004","article-title":"Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives","volume":"63","author":"Dias","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.100827","article-title":"Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives","volume":"77","author":"Garafalo","year":"2020","journal-title":"Prog. Retin Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2016.09.001","article-title":"In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies","volume":"56","author":"Yanik","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.biopha.2022.112911_bib213","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/08820538.2019.1620808","article-title":"Current stem-cell approaches for the treatment of inherited retinal degenerations","volume":"34","author":"Terrell","year":"2019","journal-title":"Semin. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib214","doi-asserted-by":"crossref","DOI":"10.3390\/genes11101120","article-title":"Mechanisms of photoreceptor death in retinitis pigmentosa","volume":"11","author":"Newton","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.biopha.2022.112911_bib215","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archopht.1993.01090060049022","article-title":"A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa","volume":"111","author":"Berson","year":"1993","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib216","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/archopht.122.9.1297","article-title":"Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosareceiving vitamin A treatment","volume":"122","author":"Berson","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib217","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1167\/iovs.15-17786","article-title":"Docosahexaenoic acid slows visual field progression in X-linked retinitis pigmentosa: ancillary outcomes of the DHAX trial","volume":"56","author":"Hoffman","year":"2015","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib218","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2415-6-23","article-title":"Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebo-controlled clinical trial [NCT00029289]","volume":"6","author":"Bahrami","year":"2006","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/585729","article-title":"Long-term effects of Nilvadipine against progression of the central visual field defect in retinitis pigmentosa: an extended study","volume":"2013","author":"Nakazawa","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2022.112911_bib220","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/jnci\/djr246","article-title":"Opportunities and challenges in the development of experimental drug combinations for cancer","volume":"103","author":"Humphrey","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2022.112911_bib221","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrd1501","article-title":"Cardiovascular combinations","volume":"3","author":"Glass","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112911_bib222","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1067\/mai.2001.112939","article-title":"Advair: Combination treatment with fluticasone propionate\/salmeterol in the treatment of asthma","volume":"107","author":"Nelson","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.biopha.2022.112911_bib223","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1126\/science.7542804","article-title":"Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy","volume":"269","author":"Larder","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112911_bib224","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.1056072","article-title":"Principles for the buffering of genetic variation","volume":"291","author":"Hartman","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112911_bib225","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature02636","article-title":"Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast","volume":"429","author":"Papp","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112911_bib226","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrd2195","article-title":"A robustness-based approach to systems-oriented drug design","volume":"6","author":"Kitano","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112911_bib227","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nature05289","article-title":"A network dysfunction perspective on neurodegenerative diseases","volume":"443","author":"Palop","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112911_bib228","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"Barab\u00e1si","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biopha.2022.112911_bib229","doi-asserted-by":"crossref","unstructured":"H. Weil-Malherbe, D.C. Wmhington, The biochemistry of the functional psychoses*, 1967.","DOI":"10.1002\/9780470122747.ch9"},{"key":"10.1016\/j.biopha.2022.112911_bib230","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112911_bib231","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a single drug: multitarget drugs","volume":"20","author":"Bolognesi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112911_bib232","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/jm401144z","article-title":"Drug design targeting protein\u2013protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6\/GP130 interface","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112911_bib233","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: is it really $802 million?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Aff."},{"key":"10.1016\/j.biopha.2022.112911_bib234","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1056\/NEJMra1602972","article-title":"FDA regulation of prescription drugs","volume":"376","author":"Gassman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib235","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.clinthera.2018.04.011","article-title":"Assessing the financial benefits of faster development times: the case of single-source versus multi-vendor outsourced biopharmaceutical manufacturing","volume":"40","author":"DiMasi","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2022.112911_bib236","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","article-title":"Amantadine: the journey from fighting flu to treating Parkinson disease","volume":"78","author":"Hubsher","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.112911_bib237","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib238","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Reviews of anti\u2010infective agents: liposomal Amphotericin B for the treatment of visceral Leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib239","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1463-1326.2010.01304.x","article-title":"Bromocriptine: old drug, new formulation and new indication","volume":"12","author":"Holt","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2022.112911_bib240","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1037\/0893-164X.18.4.362","article-title":"Effect of bupropion on depression symptoms in a smoking cessation clinical trial","volume":"18","author":"Lerman","year":"2004","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.biopha.2022.112911_bib241","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2011.01.012","article-title":"Targeting apoptosis pathways by Celecoxib in cancer","volume":"332","author":"Jendrossek","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2022.112911_bib242","first-page":"81","article-title":"Treatment of stress urinary incontinence with duloxetine hydrochloride","volume":"7","author":"Sweeney","year":"2005","journal-title":"Rev. Urol."},{"key":"10.1016\/j.biopha.2022.112911_bib243","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1529-8019.2011.01441.x","article-title":"Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up","volume":"24","author":"Rossi","year":"2011","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.biopha.2022.112911_bib244","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM199506083322301","article-title":"Fluoxetine in the treatment of premenstrual dysphoria","volume":"332","author":"Steiner","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s disease","volume":"8","author":"Lilienfeld","year":"2006","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.biopha.2022.112911_bib246","unstructured":"R.S. King, Gemcitabine. New first-line therapy for pancreatic cancer. Cancer Pract. 4 (n.d.) 353\u2013354. \u3008http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9128490\u3009."},{"key":"10.1016\/j.biopha.2022.112911_bib247","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","volume":"74","author":"Burmester","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib248","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1067\/mjd.2002.124088","article-title":"A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men","volume":"47","author":"Olsen","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.biopha.2022.112911_bib249","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1161\/01.CIR.0000109694.58299.A0","article-title":"Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent","volume":"109","author":"Gershlick","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112911_bib250","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/00002018-200528080-00006","article-title":"Benefit-risk assessment of raloxifene in postmenopausal osteoporosis","volume":"28","author":"Cranney","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2022.112911_bib251","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archneur.55.9.1211","article-title":"Ropinirole for the treatment of early Parkinson disease: a 12-month experience","volume":"55","author":"Sethi","year":"1998","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib252","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.112911_bib253","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00109-016-1450-z","article-title":"The molecular mechanism of thalidomide analogs in hematologic malignancies","volume":"94","author":"Lindner","year":"2016","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib254","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112911_bib255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic","volume":"85","author":"Broder","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2022.112911_bib256","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1479-5876-9-115","article-title":"Combination therapy: the next opportunity and challenge of medicine","volume":"9","author":"Ascierto","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib257","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1021\/jm3015926","article-title":"Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers","volume":"56","author":"Trippier","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112911_bib258","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.biopha.2022.112911_bib259","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-079X.2010.00778.x","article-title":"Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells","volume":"49","author":"Romero","year":"2010","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.biopha.2022.112911_bib260","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0306-4522(02)00912-0","article-title":"Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia","volume":"118","author":"Sobrado","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2022.112911_bib261","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2022.112911_bib262","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.03.031","article-title":"Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks","volume":"149","author":"Lee","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2022.112911_bib263","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Jin","year":"2005","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2022.112911_bib264","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c693","article-title":"Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study","volume":"340","author":"Kelly","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2022.112911_bib265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2021.102","article-title":"Inhibition of Cytochrome P450 enzymes by drugs-molecular basis and practical applications","volume":"30","author":"Guengerich","year":"2022","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.biopha.2022.112911_bib266","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by Rifampin, Rifabutin, and Rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.112911_bib267","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tips.2005.02.007","article-title":"The efficiency of multi-target drugs: the network approach might help drug design","volume":"26","author":"Csermely","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib268","unstructured":"Alzheimer\u00b4s Drug Discovery Foundation, Alzheimer CTs Report, 2018."},{"key":"10.1016\/j.biopha.2022.112911_bib269","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/1673-5374.314305","article-title":"Current and future therapeutic strategies for the treatment of retinal neurodegenerative diseases","volume":"17","author":"Maneu","year":"2022","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.biopha.2022.112911_bib270","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2337\/db18-0682","article-title":"Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy: results of the EUROCONDOR clinical trial","volume":"68","author":"Sim\u00f3","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2022.112911_bib271","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1755-5949.2008.00065.x","article-title":"Cannabidiol: a promising drug for neurodegenerative disorders?","volume":"15","author":"Iuvone","year":"2009","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.biopha.2022.112911_bib272","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Dkowicz","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib273","article-title":"The effect of curcumin on cognition in Alzheimer\u2019s disease and healthy aging: a systematic review of pre-clinical and clinical studies","volume":"2019","author":"Voulgaropoulou","year":"1725","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2022.112911_bib274","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/OPTH.S306706","article-title":"Recent advances and disputes about curcumin in retinal diseases","volume":"15","author":"Nebbioso","year":"2021","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib275","doi-asserted-by":"crossref","DOI":"10.1002\/ptr.7273","article-title":"The clinical use of curcumin on neurological disorders: an updated systematic review of clinical trials","author":"Mohseni","year":"2021","journal-title":"Phyther. Res."},{"key":"10.1016\/j.biopha.2022.112911_bib276","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14737175.2015.1044981","article-title":"Clinical development of curcumin in neurodegenerative disease","volume":"15","author":"Hu","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.biopha.2022.112911_bib277","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/JCP.0000000000000508","article-title":"Tolerance, and enhanced efficacy of a bioavailable formulation of curcumin with fenugreek dietary fiber on occupational stress","volume":"36","author":"Pandaran Sudheeran","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib278","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.joim.2018.07.001","article-title":"Bioavailable curcumin formulations: a review of pharmacokinetic studies in healthy volunteers","volume":"16","author":"Jamwal","year":"2018","journal-title":"J. Integr. Med."},{"key":"10.1016\/j.biopha.2022.112911_bib279","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102883","article-title":"Brain delivery of supplemental docosahexaenoic acid (DHA): a randomized placebo-controlled clinical trial","volume":"59","author":"Arellanes","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2022.112911_bib280","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/ajcn\/nqab016","article-title":"DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease","volume":"113","author":"Sala-Vila","year":"2021","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.biopha.2022.112911_bib281","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jfo.2021.01.005","article-title":"Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A prospective pilot optical coherence tomography angiography study","volume":"44","author":"Sabaner","year":"2021","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib282","unstructured":"US National Library of Medicine. CinicalTrials.gov, n.d. \u3008https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT00857259?term=NCT00857259&draw=2&rank=1\u3009."},{"key":"10.1016\/j.biopha.2022.112911_bib283","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203492","article-title":"Systemic immunosuppression and risk of age-related macular degeneration","volume":"13","author":"Sandhu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.112911_bib284","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2019.101223","article-title":"Taurine and its analogs in neurological disorders: focus on therapeutic potential and molecular mechanisms","volume":"24","author":"Jakaria","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.biopha.2022.112911_bib285","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.3390\/molecules25235614","article-title":"Effects of Citicoline, Homotaurine, and Vitamin E on contrast sensitivity and visual-related quality of life in patients with primary open-angle glaucoma: a preliminary study","volume":"25","author":"Marino","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2022.112911_bib286","doi-asserted-by":"crossref","unstructured":"Isradipine versus placebo in early Parkinson disease, Ann. Intern. Med. 172 (2020) 591\u2013598. \u3008https:\/\/doi.org\/10.7326\/M19\u20132534\u3009.","DOI":"10.7326\/M19-2534"},{"key":"10.1016\/j.biopha.2022.112911_bib287","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/acn3.51300","article-title":"Isradipine plasma pharmacokinetics and exposure\u2013response in early Parkinson\u2019s disease","volume":"8","author":"Venuto","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib288","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1002\/jsfa.11109","article-title":"A positive effect of egg consumption on macular pigment and healthy vision: a systematic review and meta\u2010analysis of clinical trials","volume":"101","author":"Khalighi Sikaroudi","year":"2021","journal-title":"J. Sci. Food Agric."},{"key":"10.1016\/j.biopha.2022.112911_bib289","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/gps.4109","article-title":"Memantine improves attention and episodic memory in Parkinson\u2019s disease dementia and dementia with Lewy bodies","volume":"30","author":"Wesnes","year":"2015","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112911_bib290","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/gps.4077","article-title":"Memantine improves goal attainment and reduces caregiver burden in Parkinson\u2019s disease with dementia","volume":"29","author":"Leroi","year":"2014","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112911_bib291","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0404.2007.00943.x","article-title":"Effect of memantine on CBF and CMRO 2 in patients with early Parkinson\u2019s disease","volume":"117","author":"Borghammer","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.biopha.2022.112911_bib292","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ophtha.2018.06.017","article-title":"Oral memantine for the treatment of glaucoma","volume":"125","author":"Weinreb","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2022.112911_bib293","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12877-018-0857-5","article-title":"Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer\u2019s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients","volume":"18","author":"Blanco-Silvente","year":"2018","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.biopha.2022.112911_bib294","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib295","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40123-021-00344-3","article-title":"Metformin, a potential role in age-related macular degeneration: a systematic review and meta-analysis","volume":"10","author":"Romdhoniyyah","year":"2021","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.biopha.2022.112911_bib296","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","article-title":"Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib297","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib298","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbr.2008.09.040","article-title":"Minocycline and neurodegenerative diseases","volume":"196","author":"Kim","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2022.112911_bib299","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial","volume":"15","author":"Lawlor","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.biopha.2022.112911_bib300","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1167\/iovs.13-11650","article-title":"Treatment of geographic atrophy with subconjunctival sirolimus: results of a Phase I\/II clinical trial","volume":"54","author":"Wong","year":"2013","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib301","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awab222","article-title":"Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer\u2019s disease","author":"Matthews","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2022.112911_bib302","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041479","article-title":"Study protocol of RESCUE-ALS: a Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression","volume":"11","author":"Vucic","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopha.2022.112911_bib303","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/17482960903307805","article-title":"A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis","volume":"11","author":"Pascuzzi","year":"2010","journal-title":"Amyotroph. Lateral Scler."},{"key":"10.1016\/j.biopha.2022.112911_bib304","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/med.21661","article-title":"The clinical trial landscape in amyotrophic lateral sclerosis\u2014past, present, and future","volume":"40","author":"Wobst","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2022.112911_bib305","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib306","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00417-019-04544-3","article-title":"Salvage of the retinal ganglion cells in transition phase in Alzheimer\u2019s disease with topical coenzyme Q10: is it possible?","volume":"258","author":"Karakahya","year":"2020","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib307","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00206","article-title":"A review on mitochondrial restorative mechanism of antioxidants in Alzheimer\u2019s disease and other neurological conditions","volume":"6","author":"Kumar","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib308","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jdiacomp.2012.04.004","article-title":"The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study","volume":"26","author":"Hern\u00e1ndez-Ojeda","year":"2012","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.biopha.2022.112911_bib309","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1111\/aos.12293","article-title":"Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa","volume":"92","author":"Akiyama","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib310","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006422","article-title":"Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration","volume":"96","author":"Shiragami","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.biopha.2022.112911_bib311","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/antiox8060179","article-title":"Carotenoids and markers of oxidative stress in human observational studies and intervention trials: implications for chronic diseases","volume":"8","author":"Bohn","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2022.112911_bib312","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jn\/123.5.847","article-title":"Human serum concentrations of all-trans \u03b2- and \u03b1-carotene but not 9-cis \u03b2-carotene increase upon ingestion of a natural isomer mixture obtained from Dunaliella salina (Betatene)","volume":"123","author":"Stahl","year":"1993","journal-title":"J. Nutr."},{"key":"10.1016\/j.biopha.2022.112911_bib313","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/bjo.2009.167049","article-title":"Treatment of a retinal dystrophy, fundus albipunctatus, with oral 9-cis- -carotene","volume":"94","author":"Rotenstreich","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib314","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119899","article-title":"Decrypting the potential role of \u03b1-lipoic acid in Alzheimer\u2019s disease","volume":"284","author":"Kaur","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib315","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.oret.2020.03.019","article-title":"Orally administered alpha lipoic acid as a treatment for geographic atrophy","volume":"4","author":"Kim","year":"2020","journal-title":"Ophthalmol. Retin."},{"key":"10.1016\/j.biopha.2022.112911_bib316","series-title":"Clinical Therapeutics","article-title":"J07 What can we learn from a phase ii study with BN82451B in hd beyond safety and tolerability \u2013 clinical versus objective motor measures","author":"Bohlen","year":"2018"},{"key":"10.1016\/j.biopha.2022.112911_bib317","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/21678421.2019.1672750","article-title":"Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis","volume":"21","author":"Babu","year":"2020","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"10.1016\/j.biopha.2022.112911_bib318","doi-asserted-by":"crossref","first-page":"13435","DOI":"10.1074\/jbc.271.23.13435","article-title":"Phosphocreatine-dependent glutamate uptake by synaptic vesicles","volume":"271","author":"Xu","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112911_bib319","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211024362","article-title":"The effect of doxycycline on neuron-specific enolase in patients with traumatic brain injury: a randomized controlled trial","volume":"12","author":"Mansour","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib320","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/jnnp-2016-313541","article-title":"Doxycycline in early CJD: a double-blinded randomised phase II and observational study","volume":"88","author":"Varges","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112911_bib321","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaophthalmol.2014.93","article-title":"Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non\u2013high-risk proliferative diabetic retinopathy","volume":"132","author":"Scott","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib322","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/jnnp-2020-323271","article-title":"Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19","volume":"92","author":"Al-Chalabi","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112911_bib323","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mus.26740","article-title":"Long\u2010term edaravone efficacy in amyotrophic lateral sclerosis: post\u2010hoc analyses of Study 19 (MCI186\u201319)","volume":"61","author":"Shefner","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.biopha.2022.112911_bib324","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/mds.26308","article-title":"Ethyl-eicosapentaenoic acid treatment in Huntington\u2019s disease: a placebo-controlled clinical trial","volume":"30","author":"Ferreira","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2022.112911_bib325","unstructured":"Bayer, A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy,DR), n.d. \u3008https:\/\/ichgcp.net\/clinical-trials-registry\/NCT04477707\u3009."},{"key":"10.1016\/j.biopha.2022.112911_bib326","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.26239","article-title":"Hydroxychloroquine for primary progressive multiple sclerosis","volume":"90","author":"Koch","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib327","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(01)05623-9","article-title":"Effect of hydroxychloroquine on progression of dementia in early Alzheimer\u2019s disease: an 18-month randomised, double-blind, placebo-controlled study","volume":"358","author":"Van Gool","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112911_bib328","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00400","article-title":"The therapeutic potential of metformin in neurodegenerative diseases","volume":"9","author":"Rotermund","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2022.112911_bib329","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jama.2015.9677","article-title":"Effect of Omega-3 fatty acids, Lutein\/Zeaxanthin, or other nutrient supplementation on cognitive function","volume":"314","author":"Chew","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.112911_bib330","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/mds.23148","article-title":"Protect Study Group, A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson\u2019s disease","volume":"25","author":"Snow","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.biopha.2022.112911_bib331","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2004.07.012","article-title":"Clinical potential of minocycline for neurodegenerative disorders","volume":"17","author":"Blum","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib332","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.3390\/molecules23123305","article-title":"Overview on the effects of N-acetylcysteine in neurodegenerative diseases","volume":"23","author":"Tardiolo","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2022.112911_bib333","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/antiox8050111","article-title":"Medical and dietary uses of N-acetylcysteine","volume":"8","author":"\u0160alamon","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.biopha.2022.112911_bib334","doi-asserted-by":"crossref","unstructured":"Pioglitazone in early Parkinson\u2019s disease: a phase 2, multicentre, double-blind, randomised trial, Lancet Neurol. 14 (2015) 795\u2013803. \u3008https:\/\/doi.org\/10.1016\/S1474\u20134422(15)00144\u20131\u3009.","DOI":"10.1016\/S1474-4422(15)00144-1"},{"key":"10.1016\/j.biopha.2022.112911_bib335","doi-asserted-by":"crossref","unstructured":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease, Mov. Disord. 28 (2013) 1407\u20131415. \u3008https:\/\/doi.org\/10.1002\/mds.25362\u3009.","DOI":"10.1002\/mds.25362"},{"key":"10.1016\/j.biopha.2022.112911_bib336","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1515\/revneuro-2019-0085","article-title":"Pridopidine in the treatment of Huntington\u2019s disease","volume":"31","author":"Jab\u0142o\u0144ska","year":"2020","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib337","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.08-2473","article-title":"Effect of Ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema","volume":"50","author":"Davis","year":"2009","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib338","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4236\/wjcd.2016.62007","article-title":"Sulodexide and Alzheimer\u2019s disease: a preliminary prospective study","volume":"06","author":"Lasierra-Cirujeda","year":"2016","journal-title":"World J. Cardiovasc. Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib339","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00417-014-2746-8","article-title":"Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS)","volume":"253","author":"Song","year":"2015","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib340","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/13543784.2021.1896701","article-title":"Investigational neuroprotective compounds in clinical trials for retinal disease","volume":"30","author":"Hill","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2022.112911_bib341","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00210-021-02161-8","article-title":"Coenzyme Q10 a mitochondrial restorer for various brain disorders","volume":"394","author":"Pradhan","year":"2021","journal-title":"Naunyn. Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib342","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","article-title":"Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease","volume":"71","author":"Schwarzschild","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib343","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/865179","article-title":"Lutein, Zeaxanthin, and meso -Zeaxanthin in the clinical management of eye disease","volume":"2015","author":"Scripsema","year":"2015","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib344","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100039","article-title":"Macular pigment response to Lutein, Zeaxanthin, and meso-zeaxanthin supplementation in open-angle glaucoma","volume":"1","author":"Loughman","year":"2021","journal-title":"Ophthalmol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib345","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awv184","article-title":"Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson\u2019s disease","volume":"138","author":"Jucaite","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2022.112911_bib346","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","article-title":"Clinical evaluation of the efficacy of the P2X 7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine","volume":"71","author":"Keystone","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib347","doi-asserted-by":"crossref","unstructured":"Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial, Neurology 68 (2007) 1800\u20131808. \u3008https:\/\/doi.org\/10.1212\/01.wnl.0000260269.93245.d2\u3009.","DOI":"10.1212\/01.wnl.0000260269.93245.d2"},{"key":"10.1016\/j.biopha.2022.112911_bib348","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112911_bib349","article-title":"Association between exenatide use and incidence of Alzheimer\u2019s disease","volume":"7","author":"Zhou","year":"2021","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.biopha.2022.112911_bib350","first-page":"59","article-title":"[Results of open post-registration clinical trials of copaxone in patients with multiple sclerosis]","author":"Zavalishin","year":"2002","journal-title":"Zh. Nevrol. Psikhiatrii Im. S.S. Korsakova. Suppl."},{"key":"10.1016\/j.biopha.2022.112911_bib351","doi-asserted-by":"crossref","unstructured":"A.N. Boyko, N.Y. Lashch, S.N. Sharanova, M.N. Zakharova, O. V. Trifonova, T.O. Simaniv, E. V. Lysogorskaya, O.E. Guryanov, S. V. Kotov, T.I. Iakushin, V.Y. Lizhdvoy, Y.A. Belova, F.A. Khabiro, N.N. Babichev, T.I. Khaibullin, E. V. Granatov, L.A. Averyanova, D. V. Sazonov, M.M. Odinak, Y. V. Trinitatsky, L.A. Tsukurov, A.I. Sergeeva, R.A. Ivanov, M.S. Shustova, [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study], Zhurnal Nevrol. i Psikhiatrii Im. S.S. Korsakova. 116 (n.d.) 61\u201367. \u3008https:\/\/doi.org\/10.17116\/jnevro201611610261\u201367\u3009.","DOI":"10.17116\/jnevro201611610261-67"},{"key":"10.1016\/j.biopha.2022.112911_bib352","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2174\/1567205017666201127163018","article-title":"Non-steroidal anti-inflammatory drugs as candidates for the prevention or treatment of Alzheimer\u2019s disease: do they still have a role?","volume":"17","author":"Villarejo-Galende","year":"2021","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.biopha.2022.112911_bib353","article-title":"CONCERTO: a randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis","author":"Comi","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.biopha.2022.112911_bib354","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/WNL.0000000000010284","article-title":"A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis","volume":"95","author":"Giovannoni","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.112911_bib355","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.410250413","article-title":"Multicenter trial of naloxone in alzheimer\u2019s disease","volume":"25","author":"Henderson","year":"1989","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2022.112911_bib356","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/WNL.0000000000007233","article-title":"Naproxen for presymptomatic Alzheimer disease","volume":"92","author":"Hershey","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.112911_bib357","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.4103\/1673-5374.274325","article-title":"Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases","volume":"15","author":"Fern\u00e1ndez-Albarral","year":"2020","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.biopha.2022.112911_bib358","first-page":"392","article-title":"Pharmacological effects of saffron and its constituents in ocular disorders from in vitro studies to clinical trials: a systematic review","volume":"19","author":"Sepahi","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib359","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1523\/JNEUROSCI.0774-17.2017","article-title":"Valproic acid for a treatment of retinitis pigmentosa: reasons for optimism and caution","volume":"37","author":"Todd","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112911_bib360","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ceca.2012.11.014","article-title":"Inhibition of L-type Ca2+ channels by curcumin requires a novel protein kinase-theta isoform in rat hippocampal neurons","volume":"53","author":"Liu","year":"2013","journal-title":"Cell Calcium"},{"key":"10.1016\/j.biopha.2022.112911_bib361","doi-asserted-by":"crossref","DOI":"10.1002\/iub.2054","article-title":"Effects of curcumin on ion channels and pumps: a review","author":"Tabeshpour","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/j.biopha.2022.112911_bib362","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/10799893.2015.1108337","article-title":"Curcumin inhibits apoptosis by regulating intracellular calcium release, reactive oxygen species and mitochondrial depolarization levels in SH-SY5Y neuronal cells","volume":"36","author":"U\u011fuz","year":"2016","journal-title":"J. Recept. Signal Transduct."},{"key":"10.1016\/j.biopha.2022.112911_bib363","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/ijms20133367","article-title":"Protective effects of curcumin ester prodrug, curcumin diethyl disuccinate against H2O2-induced oxidative stress in human retinal pigment epithelial cells: potential therapeutic avenues for age-related macular degeneration","volume":"20","author":"Muangnoi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib364","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2018.9749","article-title":"Curcumin inhibits high glucose\u2011induced inflammatory injury in human retinal pigment epithelial cells through the ROS\u2011PI3K\/AKT\/mTOR signaling pathway","author":"Ran","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2022.112911_bib365","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.intimp.2018.12.012","article-title":"Curcumin relieves depressive-like behaviors via inhibition of the NLRP3 inflammasome and kynurenine pathway in rats suffering from chronic unpredictable mild stress","volume":"67","author":"Zhang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib366","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11010-019-03668-8","article-title":"Curcumin amends Ca2+ dysregulation in microglia by suppressing the activation of P2X7 receptor","volume":"465","author":"Wang","year":"2020","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biopha.2022.112911_bib367","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3109\/10641969509033643","article-title":"Metformin attenuates agonist-stimulated calcium transients in vascular smooth muscle cells","volume":"17","author":"Sharma","year":"1995","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.biopha.2022.112911_bib368","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1139\/cjpp-2020-0373","article-title":"Metformin alleviates hydrogen peroxide\u2013induced inflammation and oxidative stress via inhibiting P2X7R signaling in spinal cord tissue cells neurons","volume":"99","author":"Wang","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib369","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11302-015-9490-3","article-title":"Saffron reduces ATP-induced retinal cytotoxicity by targeting P2X7 receptors","volume":"12","author":"Corso","year":"2016","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.biopha.2022.112911_bib370","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.pharep.2014.01.005","article-title":"Protection of differentiated neuronal NG108-15 cells from P2X7 receptor-mediated toxicity by taurine","volume":"66","author":"Chao","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2022.112911_bib371","unstructured":"EMA, Ebixa. Summary of product characteristics, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib372","unstructured":"FDA, Namenda. Prescribing information, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib373","unstructured":"DrugBank, Memantine, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib374","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S0039-6257(01)00200-4","article-title":"Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey","volume":"45","author":"Hare","year":"2001","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib375","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/pharmaceutics13091339","article-title":"Comprehensive evidence of carrier-mediated distribution of amantadine to the retina across the blood\u2013retinal barrier in rats","volume":"13","author":"Shinozaki","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2022.112911_bib376","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3897\/rrpharmacology.7.60380","article-title":"In vivo study of pharmacokinetic parameters of a new combination drug based on citicoline and memantine","volume":"7","author":"Sysuev","year":"2021","journal-title":"Res. Results Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib377","first-page":"19","article-title":"Pharmacokinetics and clinical efficacy of pioglitazone","author":"Hanefeld","year":"2001","journal-title":"Int. J. Clin. Pract. Suppl."},{"key":"10.1016\/j.biopha.2022.112911_bib378","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-2000-8525","article-title":"Clinical pharmacokinetics of pioglitazone","volume":"108","author":"Eckland","year":"2000","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.biopha.2022.112911_bib379","unstructured":"DrugBank, Pioglitazone, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib380","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00280-013-2084-2","article-title":"The PPAR\u03b3 agonist pioglitazone crosses the blood\u2013brain barrier and reduces tumor growth in a human xenograft model","volume":"71","author":"Grommes","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib381","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4103\/ijp.IJP_403_17","article-title":"Evaluation of the possibility of selective modulation of retinal glucose transporters in diabetic complications: an experimental study","volume":"52","author":"Mishra","year":"2020","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib382","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib383","unstructured":"DrugBank, Minocycline, (n.d.)."},{"key":"10.1016\/j.biopha.2022.112911_bib384","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/jac\/dkx039","article-title":"The complexity of minocycline serum protein binding","volume":"72","author":"Zhou","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2022.112911_bib385","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","article-title":"Clinical pharmacokinetics of doxycycline and minocycline","volume":"15","author":"Saivin","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.112911_bib386","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/bcpt.12444","article-title":"Is minocycline an antiviral agent? A review of current literature","volume":"118","author":"Nagarakanti","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2022.112911_bib387","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1186\/1742-2094-10-149","article-title":"Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury","volume":"10","author":"Abcouwer","year":"2013","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2022.112911_bib388","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archophthalmol.2009.288","article-title":"Minocycline inhibition of photoreceptor degeneration","volume":"127","author":"Yang","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib389","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/vop.12105","article-title":"Evaluation of potential topical and systemic neuroprotective agents for ocular hypertension-induced retinal ischemia-reperfusion injury","volume":"17","author":"Chen","year":"2014","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.biopha.2022.112911_bib390","unstructured":"S. Nazarian, H. Akhondi, Minocycline, n.d. \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554519\/\u3009."},{"key":"10.1016\/j.biopha.2022.112911_bib391","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1097\/00005344-199412001-00014","article-title":"Nilvadipine: profile of a new calcium antagonist. An overview","volume":"24 Suppl 2","author":"Rosenthal","year":"1994","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib392","first-page":"75","article-title":"Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog","volume":"55","author":"Niwa","year":"1987","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib393","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/j.1552-4604.1987.tb02170.x","article-title":"Pharmacokinetics of Nilvadipine in healthy volunteers","volume":"27","author":"Terakawa","year":"1987","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib394","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00005344-199212071-00004","article-title":"Pharmacokinetics of nilvadipine","volume":"20 Suppl 6","author":"von Nieciecki","year":"1992","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib395","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2165\/00002512-199506020-00007","volume":"6","author":"Brogden","year":"1995","journal-title":"Drugs Aging"},{"key":"10.1016\/j.biopha.2022.112911_bib396","unstructured":"DrugBank, NIlvadipine, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib397","doi-asserted-by":"crossref","unstructured":"A. Uemura, A. Mizota, Retinal concentration and protective effect against retinal ischemia of nilvadipine in rats, Eur. J. Ophthalmol. 18 (n.d.) 87\u201393. \u3008https:\/\/doi.org\/10.1177\/112067210801800115\u3009.","DOI":"10.1177\/112067210801800115"},{"key":"10.1016\/j.biopha.2022.112911_bib398","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cpdd.925","article-title":"Evaluation of pharmacokinetics, safety, and drug\u2010drug interactions of an oral suspension of edaravone in healthy adults","volume":"10","author":"Shimizu","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.biopha.2022.112911_bib399","unstructured":"EMA, Radicava. Withdrawal assessment report, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib400","unstructured":"Drugbank, Edaravone, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib401","first-page":"25","article-title":"Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis","volume":"43","author":"Cruz","year":"2018","journal-title":"P T"},{"key":"10.1016\/j.biopha.2022.112911_bib402","unstructured":"C. Fong, Improved Edaravone delivery to the brain and crossing the blood brain barrier: using quantum mechanics. [Research Report] Eigenenergy, Adelaide, Australia, 2019. ffhal-02292553v2f, n.d. \u3008https:\/\/hal.archives-ouvertes.fr\/hal-02292553\/document\u3009."},{"key":"10.1016\/j.biopha.2022.112911_bib403","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.341","article-title":"Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma","volume":"8","author":"Akaiwa","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib404","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000353680","article-title":"Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen","volume":"36","author":"Kaste","year":"2013","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.biopha.2022.112911_bib405","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5414\/CP201646","article-title":"Low absolute bioavailability of oral naloxone in healthy subjects","volume":"50","author":"Smith","year":"2012","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.112911_bib406","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7609.1000240","article-title":"Sublingual absorption of naloxone in a large clinical population","volume":"09","author":"Strickland","year":"2018","journal-title":"J. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2022.112911_bib407","unstructured":"DrugBank, Naloxone, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib408","series-title":"Pain Management","first-page":"939","article-title":"Opioid analgesics","author":"Koyyalagunta","year":"2007"},{"key":"10.1016\/j.biopha.2022.112911_bib409","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1111\/bph.13246","article-title":"A polyspecific drug\/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retinal barrier","volume":"172","author":"Chapy","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib410","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01170-18","article-title":"Ceftriaxone absorption enhancement for noninvasive administration as an alternative to injectable solutions","volume":"62","author":"Ba","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.112911_bib411","unstructured":"N. Dailymed, Ceftriaxone, n.d. \u3008https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=4d1ad77f-2c6b-4250\u201382e5-ab3574444e08\u3009."},{"key":"10.1016\/j.biopha.2022.112911_bib412","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.20.5.634","article-title":"Pharmacokinetics of ceftriaxone in humans","volume":"20","author":"Patel","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.112911_bib413","unstructured":"DrugBank, Ceftriaxone, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib414","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1128\/AAC.37.7.1518","article-title":"Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges","volume":"37","author":"Nau","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2022.112911_bib415","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cmi.2019.01.017","article-title":"Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics","volume":"25","author":"Brockhaus","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.biopha.2022.112911_bib416","first-page":"2179","article-title":"The intravitreal penetration of ceftriaxone in man following systemic administration","volume":"30","author":"Sharir","year":"1989","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib417","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.2010.05627.x","article-title":"Animal and human studies with the mitochondria-targeted antioxidant MitoQ","volume":"1201","author":"Smith","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2022.112911_bib418","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1874467212666181127151059","article-title":"Mitochondria-targeted drugs","volume":"12","author":"Zinovkin","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112911_bib419","series-title":"Quinones and Quinone Enzymes","author":"Sies","year":"2004"},{"key":"10.1016\/j.biopha.2022.112911_bib420","unstructured":"K.M. Taylor, R.A.J. Smith, Mitoquinone derivatives used as mitochondrially targeted antioxidants, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib421","first-page":"1","article-title":"Strategies for oral delivery and mitochondrial targeting of CoQ10","author":"Zaki","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2022.112911_bib422","doi-asserted-by":"crossref","first-page":"9293","DOI":"10.1021\/ja110190t","article-title":"Calcium binding and transport by coenzyme Q","volume":"133","author":"Bogeski","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2022.112911_bib423","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/13543781003727495","article-title":"Therapeutic use of coenzyme Q 10 and coenzyme Q 10 -related compounds and formulations","volume":"19","author":"Villalba","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2022.112911_bib424","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/hmg\/ddq467","article-title":"Evidence of severe mitochondrial oxidative stress and a protective effect of low oxygen in mouse models of inherited photoreceptor degeneration","volume":"20","author":"Vlachantoni","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2022.112911_bib425","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-198815060-00002","article-title":"Clinical pharmacokinetics of valproic acid--1988","volume":"15","author":"Zaccara","year":"1988","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.112911_bib426","unstructured":"DrugBank, Valproic acid, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib427","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00003088-198005010-00002","article-title":"Clinical pharmacokinetics of valproic Acid1","volume":"5","author":"Gugler","year":"1980","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biopha.2022.112911_bib428","unstructured":"FDA, Depakene prescribing information, n.d."},{"key":"10.1016\/j.biopha.2022.112911_bib429","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1248\/bpb.b17-00090","article-title":"Influx transport of cationic drug at the blood\u2013retinal barrier: impact on the retinal delivery of neuroprotectants","volume":"40","author":"Kubo","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.biopha.2022.112911_bib430","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/jps.23171","article-title":"Application of membrane permeability evaluated in in vitro analyses to estimate blood\u2013retinal barrier permeability","volume":"101","author":"Kubo","year":"2012","journal-title":"J. Pharm. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222003006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222003006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:21:59Z","timestamp":1774250519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222003006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":430,"alternative-id":["S0753332222003006"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112911","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined drug triads for synergic neuroprotection in retinal degeneration","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112911"}}